Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, has today sold 596,006 shares in the company at an average price of NOK 9.5245 per share. Following these transactions, Langøya Invest AS and closely related parties hold 800,000 shares in Ultimovacs ASA.
Visit link:
Ultimovacs ASA: Mandatory notification of trade by primary insiders
FREMONT, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company's manufacturing capacity to meet the growing worldwide demand for comprehensive cell analysis solutions.
View original post here:
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price per share of $62.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Apogee.
More here:
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock were offered by the Company. The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions.
See the article here:
Scorpius Holdings, Inc. Announces Pricing of Public Offering
Mithra reports full year 2023 financial results
Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET.
View post:
Hyloris to Report 2023 Full-Year Results on 14 March 2024
Scientists have created miniorgans from cells floating in the fluid that surrounds a fetus in the womb an advance they believe could open up new areas of prenatal medicine.
Miniorgans, or organoids, are tiny simplified structures that can be used to test new medical treatments or study how the real organs they mimic work, whether they are healthy or diseased.
Researchers from University College London and Great Ormond Street Hospital in the United Kingdom collected cells from amniotic fluid samples taken during 12 pregnancies as part of routine prenatal testing. Then, for the first time, they grew mini-organs from cells taken during active pregnancies. They envision their approach could eventually help doctors monitor and treat congenital conditions before birth and develop personalized therapies for a baby in the womb.
Were really excited about that possibility, said Mattia Gerli of University College London, an author of the study published Monday in the journal Nature Medicine.
The tissue-specific stem cells Gerli and his colleagues collected were shed by the fetus, as normally happens during pregnancy. The scientists identified which tissues the stem cells came from, and found cells from the lungs, kidneys and intestines.
Previously, mini-organs have been derived from adult stem cells, which more closely resemble adult tissue, or fetal tissue after an abortion.
Collecting cells from amniotic fluid gets around regulations about taking stem cells directly from fetal tissue, allowing these scientists to get cells from fetuses into the latter part of pregnancy. In the U.K., the legal limit for terminating a pregnancy is generally 22 weeks after conception. Scientists cant get fetal samples after that, limiting their ability to study normal human development or congenital diseases past that point.
In the U.S., abortion restrictions vary by state. Its legal in most to use fetal tissue for research, said Alta Charo, an emeritus professor of law and bioethics at the University of Wisconsin at Madison. Fetal tissue is defined by the National Institutes of Health as coming from a dead human embryo or fetus after a miscarriage, abortion or stillbirth and the use of tissue from an abortion has long been controversial.
Story continues
Charo, who wasn't involved in the study, said the new approach doesnt raise the same ethical issues. Obtaining cells from amniotic fluid that is already being sampled for standard clinical purposes does not appear to add any physical risks to either fetus or pregnant woman, she said in an email.
Dr. Arnold Kriegstein, who directs the Developmental and Stem Cell Biology Program at the University of California, San Francisco, and also wasn't involved in the research, said getting cells this way has the potential of giving you some information about that individual fetus as its growing.
And since growing mini-organs from cells in amniotic fluid takes about 4 to 6 weeks, Gerli said, there's enough time for prenatal therapy to fix problems doctors might find.
To examine one practical use of their approach, the U.K. team worked with colleagues in Belgium to study the development of babies with a condition called a congenital diaphragmatic hernia, in which organs such as the liver and intestines get displaced into the chest because of a hole in the diaphragm. The lungs dont develop the way they should, and about 30% of fetuses with the condition die. If doctors detect the hernia, they can operate on the fetus while it's still in the womb.
Researchers grew lung organoids from the cells of fetuses with the condition before and after treatment and compared them to organoids from healthy fetuses. Dr. Paolo de Coppi, an author of the study from University College London and Great Ormond Street Hospital, said they were able to assess the affected child's condition before birth using this method. Doctors are now unable to tell families much about the outcome of a prenatal diagnosis because each case is different, he said. The ability to study functioning prenatal miniorgans, he added, is the first step toward a more detailed prognosis and more effective treatments.
Kriegstein said more research is needed. Its in the very early stages," he added, "and well have to wait and see how useful itll be in the long run.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Science and Educational Media Group. The AP is solely responsible for all content.
Laura Ungar, The Associated Press
Originally posted here:
Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada
Novo Nordisk Foundation will invest up to $343 million over a ten-year period to establish an international research center focused on stem cell medicine.
The center is a partnership entitled reNEW between the University of Copenhagen, Denmark, Murdoch Childrens Research Institute, Australia, and Leiden University Medical Center, The Netherlands.
The aim of the collaboration is to drive future stem cell-based treatments. The governing hub will be based at the Faculty of Health and Medical Sciences, University of Copenhagen and Melissa Little from the Murdoch Childrens Research Institute will serve as the CEO of the reNEW partnership, as well as being appointed executive director and professor of the center.
Image: Melissa Little, CEO of reNEW
reNEW builds international critical mass, expands the horizons and facilities available to all sites and enables the creation of international teams working towards targeted outcomes, Little told us.
She continued: Stem cell biology has come of age. The challenge now is to apply this understanding to outcomes that will benefit society whilst supporting these on research excellence.
Experts across the three institutions will work together to develop therapeutic options for patients with incurable diseases. According to the organization, the combination of exchange programs and joint technology platforms in the reNEW model will drive the partnership and train upcoming scientists in translational stem medicine.
My aim is to create an incentivized structure in which together the researchers can pivot to targeted product development and deliver these outcomes by creating more than the sum of the parts, Little said.
reNEW has separated the research into three themes, which includes the following:
reBUILD theme: This will focus on the use of stem cells to regenerate and/or recreate tissue once it has been damaged or destroyed. Programmes include stem cell-based therapies for diseases such as congenital heart disease, diabetes, ulcerative colitis and chronic renal disease, and Parkinsons disease.
reSOLVE theme: This sees the collaboration search for potential drug candidates using stem cell-based models of human tissue. This includes lab grown models of mini-organs to treat conditions like chronic ulceration and inherited kidney and heart disease.
reWRITE theme: This will use a combination of gene editing and stem cell technologies to produce treatment strategies for genetically inherited diseases. For example, immune deficiency disorders and progressive congenital muscle disorders.
My particular area of interest is kidney disease, said Little. While we are now able to recreate models of the human kidney from pluripotent stem cells, we wish to apply these to screen for treatments for inherited kidney disease and ultimately to bioengineer transplantable kidney tissue.
The $343 million funding will support 24 groups across the three sites together with advanced facilities available and accessible to researchers across the consortium.
Read more here:
$343m investment to build stem-cell research center - BioProcess Insider - BioProcess Insider
Introduction:
The global Cell Isolation/Cell Separation Market is on an unprecedented trajectory, projected to reach a staggering USD 17.3 billion by 2025, as reported by Report Ocean Market Research. This surge is underpinned by a myriad of factors, including the evolving landscape of medical research, the surge in stem cell isolation practices, and the increasing emphasis on personalized medicines. With North America currently dominating the market, closely followed by Europe and the Asia Pacific, the Cell Isolation/Cell Separation Market is witnessing a transformative phase with a focus on driving innovation for treating diseases like cancer.
Request To Download Free Sample of This Strategic Report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Market Dynamics:
For an in-depth analysis, you can refer sample copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Get a Free Sample PDF copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Key Market Players:
Leading the charge in the Cell Isolation/Cell Separation Market are prominent players like Thermo Fisher Scientific, BD Biosciences, Beckman Coulter, Merck & Company, GE Healthcare, STEMCELL Technologies Inc., Terumo BCT, Bio-Rad Laboratories Inc., PluriSelect Life Sciences, Sigma-Aldrich Corporation, Clontech Laboratories, and Miltenyi BioTec. These companies are at the forefront of technological advancements, relentlessly pursuing breakthroughs in personalized medicine and cell research.
Conclusion:
As the Cell Isolation/Cell Separation Market hurtles toward a projected valuation of USD 17.3 billion by 2025, it stands as a testament to the remarkable strides in medical research and treatment methodologies. The convergence of technological innovation, a surge in stem cell practices, and the global shift towards personalized medicine are reshaping the landscape of healthcare. The markets dynamics, driven by research and development, government funding, and a growing interest in stem cell isolation, underscore its transformative potential.
The dominance of consumables, the varied techniques employed, and the focus on human cell isolation collectively paint a comprehensive picture of a market on the cusp of revolutionary breakthroughs. As North America retains its stronghold and the Asia Pacific emerges as a powerhouse, the global community is poised to witness pioneering advancements in precision medicine and disease treatment. The market players, with their unwavering commitment to innovation, are steering the Cell Isolation/Cell Separation Market toward a future where tailored medical solutions redefine the boundaries of possibility.
These responses will function a complete examination of the:
Access Full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=5257
Report Ocean is a renowned provider of market research reports, offering high-quality insights to clients in various industries. Their goal is to assist clients in achieving their top line and bottom line objectives, thereby enhancing their market share in todays competitive environment. As a trusted source for innovative market research reports, Report Ocean serves as a comprehensive solution for individuals, organizations, and industries seeking valuable market intelligence.
Email:sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, United States
Telephone: +1 888 212 3539 (US Toll-Free)
For more information and to explore their offerings, visit their website at:https://www.reportocean.com/
See original here:
Cell Isolation/Cell Separation Market Growth, Development Factors, Business Insights, Value Chain and Sales ... - Taiwan News
Determining the right path for multiple myeloma treatment is often complex as various decisions can significantly impact patient outcomes. Among these decisions, the consideration of autologous hematopoietic stem cell transplantation (HSCT) stands as a cornerstone, offering hope for improved progression-free and overall survival. However, recent research from Chakra Chaulagain, MD, showed that a small yet significant percentage of patients are refusing this potentially life-saving procedure.
An analysis of National Cancer Database (NCDB) data presented at the 2023 American Society of Hematology Annual Meeting showed that of 43,653 patients with newly diagnosed multiple myeloma recommended for HSCT, 98.05% proceeded with the procedure. However, the remaining 2% opted out. Some of the key factors influencing the patient's decision regarding HSCT related to socioeconomic, racial, and geographic disparities.
According to Chaulagain, director of the multiple myeloma and amyloidosis program at Cleveland Clinic Florida, older patients with multiple myeloma, those with comorbidities, and those lacking robust insurance coverage are more likely to decline HSCT. Furthermore, Black patients exhibited higher rates of refusal compared with White patients (OR, 1.38; P =.0022).
These findings underscore the need for future studies and policy changes to address socioeconomic and racial disparities in access to transplantation.
In an interview with Targeted OncologyTM, Chaulagain discussed the trends of rates of autologous HSCT refusal among patients with multiple myeloma.
Targeted Oncology: What led to your research on autologous HSCT refusal rates among patients with multiple myeloma?
Chaulagain: There is minimal data on real-world findings about refusal of a standard-of-care, for example, stem cell transplantation in [patients with] multiple myeloma. We wanted to explore some ideas about what are the factors that are contributing to the refusal transplant, which is the current standard-of-care, and it is known to improve both progression-free and overall survival based on randomized clinical trials. But there is limited real-world data around this subject, so we decided to investigate the NCDB.
Tumor microenvironment background with cancer cells, T-Cells, nanoparticles, molecules, and blood vessels. Oncology research concept: ratatosk - stock.adobe.com
What were the methods and design of this analysis?
This is a retrospective analysis of a very large number of [patients with] multiple myeloma that were treated by a commission of cancer-accredited cancer centers throughout the United States. There are at least 1500 of these types of cancer centers, and they report to this NCDB, where they have all of this data collected. NCDB captures about 70% of all cancer cases in the United States. We decided to get those data and analyze them just for multiple myeloma with the purpose of finding what are the variables and clinical factors that are responsible for refusal of autologous stem cell transplantation in [patients with] myeloma.
What were the key findings regarding the utilization of autologous HSCT in patients with multiple myeloma?
We had 43,600 patients [with] newly diagnosed multiple myeloma, and they were recommended to undergo a stem cell transplantation after completing their initial induction therapy by their doctors. Ninety-eight percent of the patients did go and do the stem cell transplantation, but 2% refused. We analyzed the various socioeconomic, racial, ethnic, and geographic factors about what made them refuse the stem cell transplantation.
Did the study identify any patient subgroups who were more likely to refuse?
We did find that older patients had a higher odds of refusing essential transplantation. Male [patients] had higher odds of accepting transplantation and females had higher odds of refusing it. Patients with more major medical comorbidities had higher odds of refusing it. Patients without insurance, or Medicare and Medicaid, had higher odds of refusing stem cell transplantation compared with patients who had private insurance. Median household income was also a significant predictor of whether the patient will go for a stem cell transplant or not. Those who were earning less than $63,000 annually had a higher odds of refusing autologous stem cell transplantation. Black patients, for example, had a higher odds of refusing transplantation, and Hispanic [patients] had a lower odds of refusing transplantation.
Were there any significant trends in the refusal rates over this time period?
The study time point was from 2004 until 2020. Patients who were diagnosed and treated closer to 2020 had a higher odds of refusing transplantation, and patients who were diagnosed closer to 2004 had a higher odds of accepting transplantation or lower odds of refusing transplantation, and we think it may have to do with advancement in novel therapies, particularly monoclonal antibody therapies in multiple myeloma in the current years.
What are the potential reasons as to why patients refused more than others?
The higher age, decreased income, not having strong private insurance, and also, the facility type did matter. For example, patients who were treated at nonacademic facilities had a higher odds of refusing transplant compared with patients that were treated at academic centers. There was also regional variation on whether the patient would refuse or accept transplant. For example, in South Atlantic states in the United States, patients had higher odds of refusing transplantation.
What are the implications of these findings?
We found that there was significant variation across the United States in terms of racial, economic, and geographic variation, and this data can and should be used for designing future clinical studies in a prospective basis.
How have recent advancements in the multiple myeloma space such as the emergence of novel therapies impacted transplantation?
Based on our studies, the emergence of novel therapies and immunotherapy, particularly anti-CD38 monoclonal antibodies like daratumumab [Darzalex], have led to decrease utilization of transplant, and it will probably further evolve down the road because of the availability of even more effective novel therapies such as [chimeric antigen receptor] T-cell therapy, and bispecific T-cell engager therapy. The role of transplant will continue to evolve and will probably continue to diminish down the road.
What barriers still need to be addressed regarding transplant?
These are bigger decisions at the policy and procedure and legislation [levels], like increasing incidence coverage, increasing socioeconomic aspects for all of our patients, particularly those who are marginalized or who are minorities. This is a bigger, national goal and the legislator has to act on it,
Read more from the original source:
Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology